XERS

Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc. (XERS) has 14 SEC Form 4 filings (19 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Jul 7, 2026.

The most active filer is See Remarks Hecht Beth with 4 filings. Insiders have net sold $2.0M over the trailing 6 months.

  • Industry:Biotechnology
  • CEO:John Shannon
  • Employees:394
  • HQ:Chicago, IL, US
  • IPO:2018-06-21

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$2.0M

reported sales (SEC code S)

Unique Insiders

8

in the rolling window

Market Cap

$1.4B

latest known value

Source
Pieper StevenFirst filing
Sale$148KJul 7SEC ↗
Pieper StevenFirst filing
Sale$235KJul 7SEC ↗
McCulloch KevinFirst filing
Sale$723KJul 2SEC ↗
Sale$134KJul 2SEC ↗
PERSKY MARLAFirst filing
Sale$91KJun 5SEC ↗
HALKUFF DAWNFirst filing
Sale$122KJun 5SEC ↗
Sale$91KJun 5SEC ↗
Sale$98KJun 5SEC ↗
Sale$101KJun 2SEC ↗
Sale$104KMay 1SEC ↗
Hecht BethFirst filing
Sale$100KApr 3SEC ↗
Sale$60KApr 1SEC ↗

Related companies

Xeris Biopharma Holdings, Inc. is in the Healthcare sector.